Cedric Ververken (ir.Ph.D.) - CEO, joined Confo Therapeutics in October 2016 from Ablynx NV where he was Vice President Business Developmentand played a key role in landmark deals for Ablynx. Prior to moving to business development he worked through various R&D functions at Ablynx, first as a scientist in the pharmacology group and later as project manager, leading cross-functional project teams from discovery up to Phase II clinical studies. He therefore brings over 10 years of R&D and business development experience to valorize Confo Therapeutics’ assets and technology.
MEET CEDRIC VERVERKEN AT #KFG2018
Cedric Ververken will give a presentation in the session "Partnering Opportunities", together with Juergen May.
"How Confo Therapeutics and Roche joined forces to crack an ‘undruggable’ GPCR"
Both companies will introduce their partnering objectives and describe where the Confo/Roche collaboration and license agreement fits in. Next we will review the different steps in the discussion (eg. how was the first link established, what the key steps were after that etc.), and briefly outlined how the deal was structured, and how this deal fits in both companies’ partnering objectives.